Mirum Pharmaceuticals, Inc. MIRM
94.42 USD +1.24 (+1.33%)
At closeNov 10, 2026, 4:00 PM EST
94.42 0.00 0.00%
After hours · Nov 10, 4:00 PM ET
91.46 Day range 95.38
63.23 52-week range 130.00
- YTD
- +19.53%
- 1 year
- +35.45%
News
reuters.com Mirum's liver infection drug lowers virus levels in second late-stage study Mirum's liver infection drug lowers virus levels in second late-stage study
businesswire.com Mirum Pharmaceuticals Announces Primary Endpoint Met in AZURE-4 Phase 3 Study and Highlights Long-Term Brelovitug Data Presented at AASLD FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Primary Endpoint Met in AZURE-4 Phase 3 Study and Highlights Long-Term Brelovitug Data Presented at AASLD.
defenseworld.net Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Sells $1,800,000.00 in Stock Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM - Get Free Report) CEO Christopher Peetz sold 20,000 shares of the company's stock in a transaction on Wednesday, November 4th. The shares were sold at an…
defenseworld.net Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Sells $1,800,000.00 in Stock Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM - Get Free Report) CEO Christopher Peetz sold 20,000 shares of the company's stock in a transaction on Wednesday, November 4th. The shares were sold at an…
benzinga.com Leerink Partners Maintains Outperform on Mirum Pharmaceuticals, Lowers Price Target to $140 Leerink Partners analyst Mani Foroohar maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and lowers the price target from $154 to $140.
businesswire.com GeneDx and Mirum Pharmaceuticals Launch Sponsored Testing Programs to Help Patients Find Answers Through Comprehensive Genetic Testing GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx and Mirum Pharmaceuticals Launch Sponsored Testing Programs to Help Patients Find Answers Through Comprehensive Genetic Testing.- benzinga.com CORRECTION: RBC Capital Reiterates Outperform on Mirum Pharmaceuticals, Maintains $155 Price Target RBC Capital analyst Lisa Walter reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and maintains $155 price target.
benzinga.com RBC Capital Reiterates Outperform on Mirum Pharmaceuticals, Maintains $155 Price Target RBC Capital analyst Luca Issi reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and maintains $155 price target.
benzinga.com Citizens Maintains Market Outperform on Mirum Pharmaceuticals, Raises Price Target to $167 Citizens analyst Jonathan Wolleben maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market Outperform and raises the price target from $144 to $167.
benzinga.com HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $202 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $200 to $202.
benzinga.com Cantor Fitzgerald Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $160 Cantor Fitzgerald analyst Josh Schimmer maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and raises the price target from $155 to $160.
benzinga.com Mirum Pharmaceuticals Q3 2026 Earnings Call Transcript Mirum Pharmaceuticals (NASDAQ:MIRM) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…- benzinga.com Mirum Pharmaceuticals Raises FY2026 Sales Guidance from $680.000M-$700.000M to $715.000M-$720.000M vs $698.093M Est Mirum Pharmaceuticals (NASDAQ:MIRM) raises FY2026 sales outlook from $680.000 million-$700.000 million to $715.000 million-$720.000 million vs $698.093 million estimate.
- benzinga.com Mirum Pharmaceuticals Q3 EPS $(0.87) Misses $(0.51) Estimate, Sales $185.721M Beat $178.078M Estimate Mirum Pharmaceuticals (NASDAQ:MIRM) reported quarterly losses of $(0.87) per share which missed the analyst consensus estimate of $(0.51) by 70.59 percent. This is a 1840 percent decrease over…
- benzinga.com Mirum Pharmaceuticals Announces Results From Cohort 2 Of Pivotal PROGRESS Study Of ATEBRIOZ - Zilurgisertib reduced total HO lesion volume and improved clinician-assessed joint mobility; no zilurgisertib-treated patients developed new HO lesions- Mirum plans to submit an sNDA in H1 2027 to…
benzinga.com TD Cowen Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $145 TD Cowen analyst Joseph Thome maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $140 to $145.
benzinga.com Stifel Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $156 Stifel analyst James Condulis maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $136 to $156.
benzinga.com Evercore ISI Group Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $146 Evercore ISI Group analyst Gavin Clark-Gartner maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and raises the price target from $135 to $146.- benzinga.com Morgan Stanley Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $152 Morgan Stanley analyst Michael Ulz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and raises the price target from $137 to $152.
- benzinga.com Citigroup Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $184 Citigroup analyst Yigal Nochomovitz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $160 to $184.
- benzinga.com HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $200 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $195 to $200.
benzinga.com Why Is Mirum Pharmaceuticals Stock Gaining Monday? Mirum stock surges after LIVMARLI wins Phase 3 trial, showing significant itch and bile acid reduction in biliary atresia patients.
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Mobile-health Network (NASDAQ:MNDR) shares increased by 141.2% to $2.05 during Monday's pre-market session. The market value of their outstanding shares is at $1.0 million. DataMEDS AI…- benzinga.com Mirum Pharmaceuticals' Phase 3 EXPAND Study Evaluating LIVMARLI Meets Primary Endpoint, Achieves Statistical Significance Across All Secondary Endpoints - Maralixibat demonstrated a statistically significant reduction in cholestatic pruritus compared with placebo (p=0.0004), and a 69% reduction in serum bile acids versus placebo (p<0.0001)- In…